85 related articles for article (PubMed ID: 21300126)
1. Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis.
Zuurmond AM; Koudijs A; van El B; Doornbos RP; van Manen-Vernooij BC; Bastiaans JH; Penninks AH; van Bilsen JH; Cnubben NH; Degroot J
Regul Toxicol Pharmacol; 2011 Apr; 59(3):461-70. PubMed ID: 21300126
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
3. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-1β in arthritic pain: main involvement in thermal, but not mechanical, hyperalgesia in rat antigen-induced arthritis.
Ebbinghaus M; Uhlig B; Richter F; von Banchet GS; Gajda M; Bräuer R; Schaible HG
Arthritis Rheum; 2012 Dec; 64(12):3897-907. PubMed ID: 22933159
[TBL] [Abstract][Full Text] [Related]
5. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.
Lee JC; Dimartino MJ; Votta BJ; Hanna N
J Immunol; 1987 Nov; 139(10):3268-74. PubMed ID: 3500212
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.
Liu D; Lon HK; Dubois DC; Almon RR; Jusko WJ
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):769-86. PubMed ID: 22002845
[TBL] [Abstract][Full Text] [Related]
7. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
Rubbert-Roth A; Perniok A
Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat.
Helyes Z; Szabó A; Németh J; Jakab B; Pintér E; Bánvölgyi A; Kereskai L; Kéri G; Szolcsányi J
Arthritis Rheum; 2004 May; 50(5):1677-85. PubMed ID: 15146439
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
11. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
Bendele AM; Chlipala ES; Scherrer J; Frazier J; Sennello G; Rich WJ; Edwards CK
Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
[TBL] [Abstract][Full Text] [Related]
12. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
[TBL] [Abstract][Full Text] [Related]
15. The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra.
van Mierlo GJ; Cnubben NH; Kuper CF; Wolthoorn J; van Meeteren-Kreikamp AP; Nagtegaal MM; Doornbos R; Ganderup NC; Penninks AH
J Immunotoxicol; 2013; 10(1):96-105. PubMed ID: 23134195
[TBL] [Abstract][Full Text] [Related]
16. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice.
Baamonde A; Curto-Reyes V; Juárez L; Meana A; Hidalgo A; Menéndez L
Life Sci; 2007 Aug; 81(8):673-82. PubMed ID: 17692876
[TBL] [Abstract][Full Text] [Related]
17. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
18. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
20. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.
Bendele A; Sennello G; McAbee T; Frazier J; Chlipala E; Rich B
J Rheumatol; 1999 Jun; 26(6):1225-9. PubMed ID: 10381034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
